Form 4: Kiniksa Pharmaceuticals Executive Sells Shares Under 10b5-1 Plan
SEC Form 4
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, sold 18,844 shares of Class A Common Stock at an average price of $21.77 on March 1, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On March 1, 2024, John F. Paolini, the Chief Medical Officer of Kiniksa Pharmaceuticals, sold 18,844 shares of Class A Common Stock.
- The sale was executed under a Rule 10b5-1 trading plan established on May 5, 2023.
- The shares were sold at an average price of $21.77, with individual trades ranging from $21.21 to $22.07.
- Paolini also acquired 18,844 shares at $1.86.
- Following the transaction, Paolini directly owns 44,892 shares of Class A Common Stock.
- Paolini also holds options for 82,217 Class A Common Shares at an exercise price of $1.86, which are fully vested and exercisable.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports a routine transaction under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to utilize 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The sale represents a small percentage of Paolini's holdings.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 05/05/2023 | Date of execution of the Rule 10b5-1 plan by the reporting person |
| 03/01/2024 | Date of the transaction (sale and acquisition of shares) |
| 03/05/2024 | Date of signature of the SEC Form 4 filing |
| 09/13/2026 | Expiration date of the Share Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.